Genomic Analysis of Extra-Nodal Natural Killer/T-Cell Lymphoma (ENKTCL)
Demographics (2)
- AGE - Age sample was collected (phv00504291.v1.p1)
- SEX - Biological sex (phv00504286.v1.p1)
Race and Ethnicity (1)
- RACE - RACE (phv00504290.v1.p1)
Other (24)
- ANALYTE_TYPE - Analyte type of the sample (phv00504308.v1.p1)
- B_SYMPTOMS - B symptoms associated with lymphoma (phv00504296.v1.p1)
- CD3 - CD3 T cell marker (phv00504302.v1.p1)
- CD56 - CD56 NK marker (phv00504301.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00504285.v1.p1)
- EBER - EBV status (phv00504300.v1.p1)
- GRAMB - Granzyme B cytotoxicity marker (phv00504303.v1.p1)
- HISTOLOGICAL_TYPE - Tumor type of sample (phv00504310.v1.p1)
- IPI_SCORE - International Prognostic Index score (phv00504297.v1.p1)
- IS_TUMOR - Tumor status (phv00504309.v1.p1)
- LATEST_STATUS - Survival status by end of the study (phv00504295.v1.p1)
- OS - Overal Survival in days (phv00504293.v1.p1)
- OS_STATUS - Overal Survival status (phv00504292.v1.p1)
- PFS - Progression-free survival in days (phv00504294.v1.p1)
- REGIMEN - Treatment regimen (phv00504299.v1.p1)
- SAMPLE_ID - Sample ID (phv00504305.v1.p1)
- SAMPLE_ID - Sample ID (phv00504288.v1.p1)
- SITE - Primary tumor location (phv00504306.v1.p1)
- STAGE - Tumor stage of sample (phv00504307.v1.p1)
- SUBJECT_ID - Subject ID (phv00504289.v1.p1)
- SUBJECT_ID - Subject ID (phv00504284.v1.p1)
- SUBJECT_ID - Subject ID (phv00504287.v1.p1)
- TIA1 - TIA1 marker (phv00504304.v1.p1)
- TREATMENT - Treatment received by the patient (phv00504298.v1.p1)